Clinical features and response to current treatment modalities in mantle cell lymphoma

  • R. I. Fisher

Abstract

This chapter addresses the important question of whether mantle cell lymphoma should be excluded from the indolent or low grade lymphomas, and presents strong evidence that it should be [10.1].

Keywords

Lymphoma Oncol Stein Anthracycline Phoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85: 1075–82.PubMedGoogle Scholar
  2. 2.
    Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328: 1002–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819–26.PubMedGoogle Scholar
  4. 4.
    Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, Rappaport H. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer 1981; 48: 1415–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6: 249–56.PubMedGoogle Scholar
  6. 6.
    Duggan MJ, Weisenburger DD, Ye YL et al. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 1990; 66: 522–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Meusers P, Engelhard M, Bartels H et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7: 365–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–62.PubMedGoogle Scholar
  9. 9.
    Narang S, Wolf BC, Neiman RS. Malignant lymphoma presenting with prominent splenomegaly. A clinicopathologic study with special reference to intermediate cell lymphoma. Cancer 1985; 55: 1948–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Pittaluga S, Wlodarska I, Stul MS et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995; 26: 17–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Berger F, Felman P, Sonet A et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83: 2829–35.PubMedGoogle Scholar
  12. 12.
    Zucca E, Fontana S, Roggero E, Pedrinis E, Pampallona S, Cavalli F. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma 1994; 13: 105–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Coiffier B, Hiddemann W, Stein H. Mantle cell lymphoma: a therapeutic dilemma. Ann Oncol 1995; 6: 208–10.PubMedGoogle Scholar
  14. 14.
    Stewart DA, Vose JM, Weisenburger DD et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263–6.PubMedGoogle Scholar

Further Reading

  1. Banks PM, Chan J, Cleary ML et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16: 637–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 1999

Authors and Affiliations

  • R. I. Fisher

There are no affiliations available

Personalised recommendations